Search

everythinglearnresearchcommunity

for

Search:↓

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

More research is needed to find the best long-term treatments for Alopecia Areata.

Lichen planus may be associated with a higher risk of metabolic syndrome.

Blocking IL-17 can reduce skin inflammation in a mouse model of pityriasis rubra pilaris.

Probiotic bacteria improved skin and hair health in aged mice.

New treatments for a chronic skin condition show promise, but individualized plans are crucial due to varying responses.

Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.

New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

Loss of a specific protein in skin cells causes symptoms similar to psoriasis.

New targeted immunotherapies are improving treatment for inflammatory skin diseases.

The study found key factors in the cause of hidradenitis suppurativa, its link to other diseases, and identified existing drugs that could potentially treat it.

Blocking certain immune signals can reduce skin damage from radiation therapy.

New treatments focusing on immune pathways show promise for stubborn hair loss.

A substance called miR-1246 may help treat severe hair loss by reducing certain immune cell activities.

Certain immune cells contribute to severe hair loss in chronic alopecia areata, with Th17 cells possibly having a bigger impact than cytotoxic T cells.

Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.

Hidradenitis suppurativa is caused by genetic factors, inflammation, bacteria, hormones, and lifestyle factors like obesity and smoking.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.

Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.

Biologics show promise in treating various stubborn skin diseases, but more research and better reimbursement criteria are needed.

The article suggests that targeting specific immune pathways could help control and treat the skin disease hidradenitis suppurativa.

Most treatments for spondyloarthritis are safe, but monitoring and careful selection based on patient risks are important.

Canine pemphigus foliaceus involves significant immune activity and shares similarities with human pemphigus.

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

IL-3 worsens lupus nephritis and blocking it improves kidney health.

Ixekizumab successfully treated a rare hair loss condition, leading to complete hair regrowth.

A specific immune response helps control mite populations on the skin, maintaining healthy hair follicles.